FindTrial
Sign In

A Study of clinical profiles of patients receiving high-emetogenic cancer chemotherapy.

Clinical Profile of Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Prospective Observational Study. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076419
Enrollment
50
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Control Intervention1: N/A: N/A

Sponsors

AIIMS RAIPUR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients (more than 18 years) diagnosed with carcinoma undergoing HEC.

Exclusion criteria

Exclusion criteria: Patients with history of nausea and vomiting in last seven days prior to administration of HEC.

Design outcomes

Primary

MeasureTime frame
A.Proportion of patients with no emesis during the acute, delayed, and protracted periods. B.Proportion of patients with no nausea during the acute, delayed, and protracted periods. Timepoint: Time Frame 24 hours 24-120 hours more than 120 hours—

Secondary

MeasureTime frame
A. Proportion of patients requiring rescue medications. B. Proportion of patients with complete and major response. Timepoint: 5 days—

Countries

India

Contacts

Public ContactAlok Singh

Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

draloksingh@aiimsraipur.edu.in9651315656

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026